个人中心 - 老虎社区

RyanT2021

Ryan learns investing.

IP属地：未知

帖子 · 60帖子 · 60
关注 · 0关注 · 0
粉丝 · 0粉丝 · 0

- RyanT2021RyanT2021
  ·2021-12-03
  Grabair 😒
  非常抱歉，此主贴已删除
  1,101 评论
  1
  分享
  举报
- RyanT2021RyanT2021
  ·2021-12-01
  Bad ama
  非常抱歉，此主贴已删除
  945 评论
  1
  分享
  举报
- RyanT2021RyanT2021
  ·2021-11-30
  Sigh new variant
  Is Omicron The Catalyst That Ushers In The Next Bear Market?
  Investors got rattled last Friday, but could the new COVID variant be the thing that finally topples stocks?
  Is Omicron The Catalyst That Ushers In The Next Bear Market?
  887 评论
  3
  分享
  举报
- RyanT2021RyanT2021
  ·2021-11-26
  Hooray
  Roche shareholders approve deal to buy Novartis's $20.7 billion stake
  ZURICH (Reuters) - Roche shareholders voted overwhelmingly on Friday to support the $20.7 billion de
  Roche shareholders approve deal to buy Novartis's $20.7 billion stake
  942 1
  6
  分享
  举报
- RyanT2021RyanT2021
  ·2021-11-16
  Ywah
  非常抱歉，此主贴已删除
  1,625 评论
  6
  分享
  举报
- RyanT2021RyanT2021
  ·2021-11-15
  Good
  非常抱歉，此主贴已删除
  782 评论
  2
  分享
  举报
- RyanT2021RyanT2021
  ·2021-11-13
  Vaccine
  Pfizer Shows Its R&D Is Strong. It’s a Good Sign for the Stock.
  Pfizer’s chief scientific officer, Mikael Dolsten, sounded giddy when reached via telephone early Mo
  Pfizer Shows Its R&D Is Strong. It’s a Good Sign for the Stock.
  1,216 1
  7
  分享
  举报
- RyanT2021RyanT2021
  ·2021-11-09
  Oh yeah AMD!
  非常抱歉，此主贴已删除
  867 3
  9
  分享
  举报
- RyanT2021RyanT2021
  ·2021-11-08
  Uh oh
  Supply chain problems crimp profit at Buffett's Berkshire Hathaway; cash sets record
  Nov 6 (Reuters) - Warren Buffett's Berkshire Hathaway Inc(BRKa.N)said on Saturday that global supply
  Supply chain problems crimp profit at Buffett's Berkshire Hathaway; cash sets record
  1,381 1
  5
  分享
  举报
- RyanT2021RyanT2021
  ·2021-11-06
  Cheers
  非常抱歉，此主贴已删除
  1,203 1
  3
  分享
  举报

热议股票

{"i18n":{"language":"zh_CN"},"isCurrentUser":false,"userPageInfo":{"id":"3584238171442752","uuid":"3584238171442752","gmtCreate":1621150723051,"gmtModify":1621159965828,"name":"RyanT2021","pinyin":"ryant2021","introduction":"","introductionEn":null,"signature":"Ryan learns investing.","avatar":"https://static.tigerbbs.com/c3aa70ae67b23e62ebdede4c992de8f8","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":4,"headSize":296,"tweetSize":60,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-1","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"出道虎友","description":"加入老虎社区500天","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.10.01","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":2,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":1,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":601946359,"gmtCreate":1638487778267,"gmtModify":1638487778377,"author":{"id":"3584238171442752","authorId":"3584238171442752","name":"RyanT2021","avatar":"https://static.tigerbbs.com/c3aa70ae67b23e62ebdede4c992de8f8","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3584238171442752","idStr":"3584238171442752"},"themes":[],"htmlText":"Grabair 😒","listText":"Grabair 😒","text":"Grabair 😒","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/601946359","repostId":"1191495883","repostType":2,"isVote":1,"tweetType":1,"viewCount":1101,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":609411200,"gmtCreate":1638317023022,"gmtModify":1638317023084,"author":{"id":"3584238171442752","authorId":"3584238171442752","name":"RyanT2021","avatar":"https://static.tigerbbs.com/c3aa70ae67b23e62ebdede4c992de8f8","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3584238171442752","idStr":"3584238171442752"},"themes":[],"htmlText":"Bad ama","listText":"Bad ama","text":"Bad ama","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/609411200","repostId":"2188956532","repostType":4,"isVote":1,"tweetType":1,"viewCount":945,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":609145054,"gmtCreate":1638257987846,"gmtModify":1638257987989,"author":{"id":"3584238171442752","authorId":"3584238171442752","name":"RyanT2021","avatar":"https://static.tigerbbs.com/c3aa70ae67b23e62ebdede4c992de8f8","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3584238171442752","idStr":"3584238171442752"},"themes":[],"htmlText":"Sigh new variant","listText":"Sigh new variant","text":"Sigh new variant","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/609145054","repostId":"1171526526","repostType":4,"repost":{"id":"1171526526","kind":"news","pubTimestamp":1638257648,"share":"https://www.laohu8.com/m/news/1171526526?lang=&edition=full","pubTime":"2021-11-30 15:34","market":"us","language":"en","title":"Is Omicron The Catalyst That Ushers In The Next Bear Market?","url":"https://stock-news.laohu8.com/highlight/detail?id=1171526526","media":"TheStreet","summary":"Investors got rattled last Friday, but could the new COVID variant be the thing that finally topples stocks?","content":"<p>There’s clearly only topic of conversation for the financial markets this week. The announcement of the omicron variant of the COVID virus put investors into a panic and sent the S&amp;P 500 to its largest single day loss since February and the Russell 2000 to its largest single day loss since June of last year. The reveal of a potentially more mutated and more highly contagious version of both the original COVID strain and the delta variant brought investors back to the early days of the pandemic when businesses, schools and other groups were suddenly forced to shut down.</p>\n<p>Is it going to be as big of a deal as the markets fear it might be? It’s too early to know for sure (although the South African Medical Association seems to be&nbsp;downplaying&nbsp;the severity of it), but global governments appear to be taking no chances. Several countries have shut down their borders to people from South Africa and neighboring countries. New York has already&nbsp;declared&nbsp;a state of emergency despite no reported cases of the omicron variant. Of course, there’s still much to learn about the risk level of this COVID strain, but it’s clear that nerves are a bit frayed.</p>\n<p>In my opinion, Friday’s sharp equity pullback looks like a classic overreaction. Yes, there’s a distinct possibility that it may not be the bottom and equities could sell off further, but given how investors have been prolific dip buyers over the past year and expectations for the taper and future interest rate hikes turned immediately dovish, per the Fed Funds futures market, I think investors will quickly conclude that the omicron variant will likely not be as bad as anticipated and, even if it is, the Fed will quickly step in, whether it’s via a delayed taper or no rate hike until 2023, to support risk asset prices. If I’m going out on a limb, I think there’s a chance the S&amp;P 500 could recapture its all-time high (it’s currently about 2.3% below it) by the end of this week.</p>\n<p>Market internals had already been softening leading up to last week. Breadth within the Nasdaq 100 has been getting weaker - 30 of the 100 components have&nbsp;pulled back&nbsp;at least 20%. Small-caps have been underperforming for weeks and leadership has rotated away from cyclicals and back into tech and consumer discretionary. Treasuries are looking strong again and even gold has been seeing some action.</p>\n<p>Fear is high in the markets right now and that presents opportunity. Keep a level head and watch for panic signs (e.g. the number of articles talking about how stocks could pull back 30% from here) and words from the Fed that hint at what the central bank might do. Remember, in 2020 after the initial bear market, stocks rebounded quickly as soon as the Fed and the government stepped in. If Powell pivots to a more dovish stance, U.S. equities could quickly move higher again.</p>\n<p>Let’s start our weekly review by taking a look at the primary market sectors.</p>\n<p><img src=\"https://static.tigerbbs.com/d87d1ba9c165a777608a551646236565\" tg-width=\"1240\" tg-height=\"958\" width=\"100%\" height=\"auto\"></p>\n<p>Not surprisingly, there’s little short-term strength in equities right now. Communication services remains the worst-looking of the 11 major sectors, but cyclicals are not that far behind. Energy stocks were down 4% on Friday as crude oil prices dropped more than 10%, but still managed to gain more than 1% on the week as a whole. Financials are weaker on falling interest rates, but industrials and materials are similarly well off recent highs.</p>\n<p>As I mentioned above, tech and consumer discretionary have been the beneficiaries of rotation trades lately. Tech had become a steady outperformer before last week’s correction, while discretionary stocks have gained but remained volatile. Four of the 11 GICS sectors are now trading below their 50-day moving averages, which could be an indication that short-term momentum has run its course and it may be time for defensives to take over.</p>\n<p>The performance of small-caps, Treasuries and cyclicals point to more conservative positioning even before Friday. Utilities and consumer staples did relatively better as expected, but it’s been a while since either group had an extended run. This week will be telling, I think, in determining where investor risk tolerance is really at. If omicron looks like it will keep drawing out people’s fears, there might be room for defensive sectors to perform relatively well. Keep in mind that it’ll be all about business and social restrictions. If the economic impact is limited mostly to the leisure and travel sectors, the longer-term damage could be minimal.</p>\n<p><img src=\"https://static.tigerbbs.com/cbc4d98c13f73357d48d25a67a1ed80e\" tg-width=\"1240\" tg-height=\"958\" width=\"100%\" height=\"auto\"></p>\n<p>Short-term strength has fallen pretty much across the board, but with a few exceptions. Semiconductor stocks had a rough week along with the rest of the tech sector, but they remain one of the best performing groups throughout 2021. Homebuilder stocks continue to build on the strength in the housing, which, despite some stops and starts in sales, demand and commodity prices, been pretty consistent.</p>\n<p>No surprise that the casino, leisure and recreation stocks are getting hit the hardest. These, of course, are the first to get hit in an environment like this. New travel restrictions are already being put in place and we’re very likely to see even more in the coming weeks. As we’ve seen with New York, there’s been little hesitation so far to put mitigation efforts in place. Oil prices and energy demand forecasts have taken a hit adding to the pressure.</p>\n<p>No major changes in the communication services sector. We’re still seeing weakness throughout, including the social media stocks, which continue to have a hard time reversing sentiment. The traditional telecoms were virtually changed this past week and could actually become a source of support should prices continue falling here.</p>\n<p><img src=\"https://static.tigerbbs.com/b04029e09b601d3f39d2cfc0be349d00\" tg-width=\"1240\" tg-height=\"958\" width=\"100%\" height=\"auto\"></p>\n<p>Oil prices got hammered last week, which led to 5-6% losses for the explorers and servicers. The broader energy sector did comparatively better, but even clean energy posted a loss of 4% indicating little support across the board. Short-term sentiment for this sector has largely disappeared and the huge returns of earlier this year have long since been forgotten. This will be an especially omicron-dependent sector this week, so expect some above average volatility. Flow numbers show that investors are abandoning ship.</p>\n<p>Just like the leisure sector, the airlines are especially weak here, but there’s really no group within the cyclicals that’s doing OK. The gold &amp; silver miners had a moment in the sun, but with gold prices appearing to have lost their momentum again, they’ve been back on the downswing. Infrastructure stock returns have largely been a function of the passage of the infrastructure bill, but that momentum it also likely to begin fading.</p>\n<p><img src=\"https://static.tigerbbs.com/4d74ecebe8c9240855b76ea5a23034f4\" tg-width=\"1240\" tg-height=\"958\" width=\"100%\" height=\"auto\"></p>\n<p>Healthcare is starting to look a little, well, healthier again. Most of it looks like it’s due to its defensive sector peers starting to draw a little interest again, but any kind of health-related headlines, such as a new COVID variant, tend to produce at least a modest short-term bounce. Both Moderna and BioNTech, the makers of different COVID vaccines, were both up more than 20% last week alone and that’s making the biotech sector look a little stronger than it is. The&nbsp;<b>SPDR S&amp;P Biotech ETF (XBI)</b>, which equal weights the sector and gives much less weight to those names, was down 4% last week. There is some money moving back into this space, but I don’t think it’s a compelling move just yet.</p>\n<p>Not much doing on the commodities side. Crude and gasoline prices have plummeted, but natural gas prices have held their ground. I suspect that there’s some mean reversion in energy prices following Friday’s overreaction. The dollar remains very strong against the basket of global currencies although we’ll have to see if the omicron variant impacts that. Its strength has come on the back of comparatively higher interest rates and better economic growth readings. The plans for tapering and rate hikes may be pushed back now, which could bring the dollar back down.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is Omicron The Catalyst That Ushers In The Next Bear Market?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs Omicron The Catalyst That Ushers In The Next Bear Market?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-30 15:34 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.thestreet.com/etffocus/market-intelligence/is-omicron-catalyst-that-ushers-in-next-bear-market><strong>TheStreet</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>There’s clearly only topic of conversation for the financial markets this week. The announcement of the omicron variant of the COVID virus put investors into a panic and sent the S&P 500 to its ...</p>\n\n<a href=\"https://www.thestreet.com/etffocus/market-intelligence/is-omicron-catalyst-that-ushers-in-next-bear-market\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".SPX":"S&P 500 Index",".IXIC":"NASDAQ Composite",".DJI":"道琼斯"},"source_url":"https://www.thestreet.com/etffocus/market-intelligence/is-omicron-catalyst-that-ushers-in-next-bear-market","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1171526526","content_text":"There’s clearly only topic of conversation for the financial markets this week. The announcement of the omicron variant of the COVID virus put investors into a panic and sent the S&P 500 to its largest single day loss since February and the Russell 2000 to its largest single day loss since June of last year. The reveal of a potentially more mutated and more highly contagious version of both the original COVID strain and the delta variant brought investors back to the early days of the pandemic when businesses, schools and other groups were suddenly forced to shut down.\nIs it going to be as big of a deal as the markets fear it might be? It’s too early to know for sure (although the South African Medical Association seems to be downplaying the severity of it), but global governments appear to be taking no chances. Several countries have shut down their borders to people from South Africa and neighboring countries. New York has already declared a state of emergency despite no reported cases of the omicron variant. Of course, there’s still much to learn about the risk level of this COVID strain, but it’s clear that nerves are a bit frayed.\nIn my opinion, Friday’s sharp equity pullback looks like a classic overreaction. Yes, there’s a distinct possibility that it may not be the bottom and equities could sell off further, but given how investors have been prolific dip buyers over the past year and expectations for the taper and future interest rate hikes turned immediately dovish, per the Fed Funds futures market, I think investors will quickly conclude that the omicron variant will likely not be as bad as anticipated and, even if it is, the Fed will quickly step in, whether it’s via a delayed taper or no rate hike until 2023, to support risk asset prices. If I’m going out on a limb, I think there’s a chance the S&P 500 could recapture its all-time high (it’s currently about 2.3% below it) by the end of this week.\nMarket internals had already been softening leading up to last week. Breadth within the Nasdaq 100 has been getting weaker - 30 of the 100 components have pulled back at least 20%. Small-caps have been underperforming for weeks and leadership has rotated away from cyclicals and back into tech and consumer discretionary. Treasuries are looking strong again and even gold has been seeing some action.\nFear is high in the markets right now and that presents opportunity. Keep a level head and watch for panic signs (e.g. the number of articles talking about how stocks could pull back 30% from here) and words from the Fed that hint at what the central bank might do. Remember, in 2020 after the initial bear market, stocks rebounded quickly as soon as the Fed and the government stepped in. If Powell pivots to a more dovish stance, U.S. equities could quickly move higher again.\nLet’s start our weekly review by taking a look at the primary market sectors.\n\nNot surprisingly, there’s little short-term strength in equities right now. Communication services remains the worst-looking of the 11 major sectors, but cyclicals are not that far behind. Energy stocks were down 4% on Friday as crude oil prices dropped more than 10%, but still managed to gain more than 1% on the week as a whole. Financials are weaker on falling interest rates, but industrials and materials are similarly well off recent highs.\nAs I mentioned above, tech and consumer discretionary have been the beneficiaries of rotation trades lately. Tech had become a steady outperformer before last week’s correction, while discretionary stocks have gained but remained volatile. Four of the 11 GICS sectors are now trading below their 50-day moving averages, which could be an indication that short-term momentum has run its course and it may be time for defensives to take over.\nThe performance of small-caps, Treasuries and cyclicals point to more conservative positioning even before Friday. Utilities and consumer staples did relatively better as expected, but it’s been a while since either group had an extended run. This week will be telling, I think, in determining where investor risk tolerance is really at. If omicron looks like it will keep drawing out people’s fears, there might be room for defensive sectors to perform relatively well. Keep in mind that it’ll be all about business and social restrictions. If the economic impact is limited mostly to the leisure and travel sectors, the longer-term damage could be minimal.\n\nShort-term strength has fallen pretty much across the board, but with a few exceptions. Semiconductor stocks had a rough week along with the rest of the tech sector, but they remain one of the best performing groups throughout 2021. Homebuilder stocks continue to build on the strength in the housing, which, despite some stops and starts in sales, demand and commodity prices, been pretty consistent.\nNo surprise that the casino, leisure and recreation stocks are getting hit the hardest. These, of course, are the first to get hit in an environment like this. New travel restrictions are already being put in place and we’re very likely to see even more in the coming weeks. As we’ve seen with New York, there’s been little hesitation so far to put mitigation efforts in place. Oil prices and energy demand forecasts have taken a hit adding to the pressure.\nNo major changes in the communication services sector. We’re still seeing weakness throughout, including the social media stocks, which continue to have a hard time reversing sentiment. The traditional telecoms were virtually changed this past week and could actually become a source of support should prices continue falling here.\n\nOil prices got hammered last week, which led to 5-6% losses for the explorers and servicers. The broader energy sector did comparatively better, but even clean energy posted a loss of 4% indicating little support across the board. Short-term sentiment for this sector has largely disappeared and the huge returns of earlier this year have long since been forgotten. This will be an especially omicron-dependent sector this week, so expect some above average volatility. Flow numbers show that investors are abandoning ship.\nJust like the leisure sector, the airlines are especially weak here, but there’s really no group within the cyclicals that’s doing OK. The gold & silver miners had a moment in the sun, but with gold prices appearing to have lost their momentum again, they’ve been back on the downswing. Infrastructure stock returns have largely been a function of the passage of the infrastructure bill, but that momentum it also likely to begin fading.\n\nHealthcare is starting to look a little, well, healthier again. Most of it looks like it’s due to its defensive sector peers starting to draw a little interest again, but any kind of health-related headlines, such as a new COVID variant, tend to produce at least a modest short-term bounce. Both Moderna and BioNTech, the makers of different COVID vaccines, were both up more than 20% last week alone and that’s making the biotech sector look a little stronger than it is. The SPDR S&P Biotech ETF (XBI), which equal weights the sector and gives much less weight to those names, was down 4% last week. There is some money moving back into this space, but I don’t think it’s a compelling move just yet.\nNot much doing on the commodities side. Crude and gasoline prices have plummeted, but natural gas prices have held their ground. I suspect that there’s some mean reversion in energy prices following Friday’s overreaction. The dollar remains very strong against the basket of global currencies although we’ll have to see if the omicron variant impacts that. Its strength has come on the back of comparatively higher interest rates and better economic growth readings. The plans for tapering and rate hikes may be pushed back now, which could bring the dollar back down.","news_type":1},"isVote":1,"tweetType":1,"viewCount":887,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":877689986,"gmtCreate":1637924331182,"gmtModify":1637924331182,"author":{"id":"3584238171442752","authorId":"3584238171442752","name":"RyanT2021","avatar":"https://static.tigerbbs.com/c3aa70ae67b23e62ebdede4c992de8f8","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3584238171442752","idStr":"3584238171442752"},"themes":[],"htmlText":"Hooray","listText":"Hooray","text":"Hooray","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/877689986","repostId":"1190474385","repostType":4,"repost":{"id":"1190474385","kind":"news","pubTimestamp":1637924231,"share":"https://www.laohu8.com/m/news/1190474385?lang=&edition=full","pubTime":"2021-11-26 18:57","market":"us","language":"en","title":"Roche shareholders approve deal to buy Novartis's $20.7 billion stake","url":"https://stock-news.laohu8.com/highlight/detail?id=1190474385","media":"Reuters","summary":"ZURICH (Reuters) - Roche shareholders voted overwhelmingly on Friday to support the $20.7 billion de","content":"<p>ZURICH (Reuters) - Roche shareholders voted overwhelmingly on Friday to support the $20.7 billion deal to buy Novartis's nearly one third voting stake, the Swiss drugmaker said.</p>\n<p>Roche held an extraordinary general meeting to settle matters related to its plan to disentangle the two pharma companies, both based in Basel, who had been linked by the investment for two decades.</p>\n<p>Shareholders approved the audited statutory interim financial statements of the company as of 31 October 2021 with a majority of 100.00%, Roche said.</p>\n<p>They also backed the plan to cancel the 53.3 million shares bought, with a majority of 99.85%.</p>\n<p>Therefore, the corporate law requirements for the repurchase have been satisfied, Roche said. The closing of the repurchase transaction is expected to take place in early December 2021.</p>\n<p>\"Today's resolutions of the Extraordinary General Meeting are in the best economic and strategic interest of Roche,\" said Roche Chairman Christoph Franz. \"As a result, we will be even better positioned to make a contribution to the health of people around the world.\"</p>\n<p>Novartis agreed earlier this month to sell 53.3 million Roche bearer shares for $388.99 (356.93 Swiss francs) per share, a price that reflected the volume-weighted average of the Roche non-voting equity certificates over the 20 trading days to Nov. 2.</p>\n<p>The repurchase was conditional upon the approval by shareholders of a capital reduction by cancellation of the repurchased shares and of the interim financial statements prepared for the transaction.</p>\n<p>Novartis' involvement started in 2001, when Swiss activist investor Martin Ebner, known for orchestrating the merger that created banking giant UBS, offered his Roche stake to its cross-town rival out of frustration over rebuffed proposals.</p>\n<p>Roche Chairman Franz said earlier this month that the deal would give his company more strategic flexibility, as Roche could now make plans without needing the approval of Novartis.</p>","source":"lsy1612507957220","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Roche shareholders approve deal to buy Novartis's $20.7 billion stake</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRoche shareholders approve deal to buy Novartis's $20.7 billion stake\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-26 18:57 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/roche-shareholders-approve-deal-buy-101846094.html><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>ZURICH (Reuters) - Roche shareholders voted overwhelmingly on Friday to support the $20.7 billion deal to buy Novartis's nearly one third voting stake, the Swiss drugmaker said.\nRoche held an ...</p>\n\n<a href=\"https://finance.yahoo.com/news/roche-shareholders-approve-deal-buy-101846094.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVS":"诺华","RHHBY":"罗氏控股"},"source_url":"https://finance.yahoo.com/news/roche-shareholders-approve-deal-buy-101846094.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1190474385","content_text":"ZURICH (Reuters) - Roche shareholders voted overwhelmingly on Friday to support the $20.7 billion deal to buy Novartis's nearly one third voting stake, the Swiss drugmaker said.\nRoche held an extraordinary general meeting to settle matters related to its plan to disentangle the two pharma companies, both based in Basel, who had been linked by the investment for two decades.\nShareholders approved the audited statutory interim financial statements of the company as of 31 October 2021 with a majority of 100.00%, Roche said.\nThey also backed the plan to cancel the 53.3 million shares bought, with a majority of 99.85%.\nTherefore, the corporate law requirements for the repurchase have been satisfied, Roche said. The closing of the repurchase transaction is expected to take place in early December 2021.\n\"Today's resolutions of the Extraordinary General Meeting are in the best economic and strategic interest of Roche,\" said Roche Chairman Christoph Franz. \"As a result, we will be even better positioned to make a contribution to the health of people around the world.\"\nNovartis agreed earlier this month to sell 53.3 million Roche bearer shares for $388.99 (356.93 Swiss francs) per share, a price that reflected the volume-weighted average of the Roche non-voting equity certificates over the 20 trading days to Nov. 2.\nThe repurchase was conditional upon the approval by shareholders of a capital reduction by cancellation of the repurchased shares and of the interim financial statements prepared for the transaction.\nNovartis' involvement started in 2001, when Swiss activist investor Martin Ebner, known for orchestrating the merger that created banking giant UBS, offered his Roche stake to its cross-town rival out of frustration over rebuffed proposals.\nRoche Chairman Franz said earlier this month that the deal would give his company more strategic flexibility, as Roche could now make plans without needing the approval of Novartis.","news_type":1},"isVote":1,"tweetType":1,"viewCount":942,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":871399532,"gmtCreate":1637023887635,"gmtModify":1637023887694,"author":{"id":"3584238171442752","authorId":"3584238171442752","name":"RyanT2021","avatar":"https://static.tigerbbs.com/c3aa70ae67b23e62ebdede4c992de8f8","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3584238171442752","idStr":"3584238171442752"},"themes":[],"htmlText":"Ywah","listText":"Ywah","text":"Ywah","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/871399532","repostId":"1140879609","repostType":4,"isVote":1,"tweetType":1,"viewCount":1625,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":873685953,"gmtCreate":1636938238621,"gmtModify":1636938238725,"author":{"id":"3584238171442752","authorId":"3584238171442752","name":"RyanT2021","avatar":"https://static.tigerbbs.com/c3aa70ae67b23e62ebdede4c992de8f8","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3584238171442752","idStr":"3584238171442752"},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/873685953","repostId":"2183048749","repostType":4,"isVote":1,"tweetType":1,"viewCount":782,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":879786919,"gmtCreate":1636773124448,"gmtModify":1636773124448,"author":{"id":"3584238171442752","authorId":"3584238171442752","name":"RyanT2021","avatar":"https://static.tigerbbs.com/c3aa70ae67b23e62ebdede4c992de8f8","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3584238171442752","idStr":"3584238171442752"},"themes":[],"htmlText":"Vaccine","listText":"Vaccine","text":"Vaccine","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/879786919","repostId":"1102251183","repostType":4,"repost":{"id":"1102251183","kind":"news","pubTimestamp":1636772424,"share":"https://www.laohu8.com/m/news/1102251183?lang=&edition=full","pubTime":"2021-11-13 11:00","market":"us","language":"en","title":"Pfizer Shows Its R&D Is Strong. It’s a Good Sign for the Stock.","url":"https://stock-news.laohu8.com/highlight/detail?id=1102251183","media":"Barrons","summary":"Pfizer’s chief scientific officer, Mikael Dolsten, sounded giddy when reached via telephone early Mo","content":"<p>Pfizer’s&nbsp;chief scientific officer, Mikael Dolsten, sounded giddy when reached via telephone early Monday morning. It was just days after his company knocked the socks off the market with the news that its Covid-19 antiviral had cut the risk of hospitalization by 89% in high-risk adults.</p>\n<p>“It can’t be just a random thing, that you’re able to beat this type of world record and get a grand slam at the same time by chance,” Dolsten said, scrambling sports metaphors as he sought to illustrate the magnitude of Pfizer’s twin wins: the development of a stunningly effective Covid-19 vaccine in just 10 months, followed a year later by the development of a similarly stunning Covid-19 antiviral.</p>\n<p>Two years ago, Pfizer (ticker: PFE) CEO Albert Bourla asked investors to take a big gamble on the research-and-development operation that Dolsten has rebuilt over the course of more than a decade. That bet is looking smarter than ever.</p>\n<p>Bourla has gotten rid of Pfizer’s off-patent drugs division and the last of its consumer health products, leaving behind a pure-play biopharma company that will live or die on the strength of Dolsten’s science.</p>\n<p>In a cover story in November 2019, <i>Barron’s</i> argued that Bourla and Dolsten could pull it off.</p>\n<p>The new antiviral data reaffirms the case for Pfizer that <i>Barron’s</i> made two years ago. Continuing to profit off the pandemic, however, brings new risks, as criticism grows over the global inequity in vaccine distribution. Low-income nations account for less than 1% of the more than seven billion doses administered worldwide. If distribution of Pfizer’s antiviral continues to favor wealthy nations, the company’s stock could ultimately suffer.</p>\n<p>Pfizer’s shares surged 10.9% the day the data came out, their best daily showing in at least 20 years. Still, with the stock now changing hands at around $50, investors continue to undervalue the company. Investors are pricing Pfizer at 12 times next year’s expected earnings, cheaper than peers like&nbsp;Johnson &amp; Johnson&nbsp;(JNJ) and&nbsp;Eli Lilly&nbsp;(LLY).</p>\n<p>The Pfizer discount can be attributed to concerns over the patent cliff the drugmaker faces at the end of the decade. The company stands to lose exclusivity over a handful of drugs that bring in billions in annual revenue.</p>\n<p>The worries are legitimate, but Pfizer’s scientific coup should give investors confidence that the company’s science can carry it safely over that cliff. It may take time for the market to catch up, but for long-term investors, it’s a promising opportunity.</p>\n<p>The success of the antiviral is the best illustration yet of Pfizer’s scientific prowess.</p>\n<p>While Pfizer’s Covid-19 vaccine came out of the labs of the German biotech&nbsp;BioNTech&nbsp;(BNTX), the new Covid-19 antiviral was whipped up by what Dolsten called a “dream team” of scientists at Pfizer’s own labs across the Northeast U.S.</p>\n<p>In the earliest days of the pandemic, Pfizer split its efforts between its collaboration with BioNTech on the vaccine and its quest for a Covid-19 pill. The vaccine effort operated on a huge scale; Dolsten called it a “mega team” that spanned the Atlantic.</p>\n<p>The antiviral project was a much smaller operation—a group of Pfizer experts operating with resources left over from the vaccine push.</p>\n<p>“The small molecule was more like a nimble, laser-focused, high-end team, with rather moderate resources,” Dolsten said.</p>\n<p>Dolsten gathered some of Pfizer’s most experienced scientists to work on the antiviral project, including its head of medicine design, Charlotte Allerton. The scientists started with work Pfizer had done years ago on a type of antiviral called a protease inhibitor.</p>\n<p>“[Pfizer’s] pharmaceutical R&amp;D is better than people had thought.”</p>\n<p>The protease inhibitors in the Pfizer library, however, had been administered intravenously, and had not worked well when delivered orally. The team had to figure out how to adapt the drugs to oral administration, a substantial undertaking.</p>\n<p>“They had to really create a lot of new chemistry,” Dolsten said. The scientists created 600 compounds to nail down the right drug, a process that might normally take years, and which they accomplished in a matter of months. “Four years turned into four months here,” he said.</p>\n<p>Pfizer started testing the pill in humans in March. It is now running a number of Phase 2/3 trials of the drug, including one for patients who are high risk, one for patients not high risk, and one as a prophylaxis for patients who have been exposed to the virus but aren’t yet sick. In the first readout, the drug looked substantially more effective than the Covid treatment pill from&nbsp;Merck&nbsp;(MRK).</p>\n<p>“It definitely helps prove the point that [Pfizer’s] pharmaceutical R&amp;D is better than people had thought,” says Louise Chen, an analyst at Cantor Fitzgerald, who has an Overweight rating and a $61 price target on the stock.</p>\n<p>Chen says that she doesn’t expect investors to come around to her way of thinking until there is more clarity on the durability of Covid-19 vaccine and pill sales, and the rest of the pipeline gets proved out.</p>\n<p>“There is not one event that I think will trigger a re-rating of the stock at the next level,” she says. “Until those things play out, I don’t think that it necessarily will.”</p>\n<p>That makes a bet on Pfizer a long-term play. In the meantime, the experience of&nbsp;Moderna&nbsp;(MRNA) in recent weeks is highlighting the potential for the vaccine makers to come under scrutiny over unequal distribution of vaccines.</p>\n<p>Biden administration officials have been increasingly frustrated with Moderna, calling on the company to ramp up production so it can offer more doses at not-for-profit prices to low-income countries, with one top official calling on the company to “step up.”</p>\n<p>Moderna shares are down more than 40% over the past three months.</p>\n<p>As the pandemic persists, Pfizer risks eroding the enormous goodwill it earned roughly a year ago when it introduced its Covid-19 vaccine. Earlier this month, Pfizer CEO Bourla blamed low-income countries for unfair vaccine distribution, telling <i>Barron’s</i> that it was their fault for not placing orders. Pfizer has sold a billion vaccine doses to the U.S. at a not-for-profit price to donate to poor countries, and says that a total of at least two billion doses will be delivered to low- and middle-income nations by the end of next year.</p>\n<p>When it comes to antivirals, Pfizer has said only that it will offer tiered pricing for poorer nations, the same approach it has taken with its vaccine.</p>\n<p>That contrasts sharply with Merck’s plan to make its own Covid-19 pill available to poor countries. Merck has signed a deal with a United Nations-backed group that will allow its pill to be licensed globally, with no royalties paid to Merck.</p>\n<p>Dolsten said that Pfizer is looking into licensing its pill under a similar mechanism as Merck’s. “We will look at those options,” he said. “By no means have we said we would do something different. We just want to make sure whoever will be involved gets the advice and skill to do this.”</p>\n<p>Such a step couldn’t come soon enough. Late last month, activists protested outside Bourla’s home, calling on Pfizer to share its vaccine manufacturing technology and to fill orders from low-income countries ahead of those from wealthy countries.</p>\n<p>An aggressive plan to share its antiviral would help stave off such criticism, keeping Pfizer in the relative good graces of Washington and allowing its impressive science to continue to drive the stock higher.</p>","source":"lsy1601382232898","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer Shows Its R&D Is Strong. It’s a Good Sign for the Stock.</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer Shows Its R&D Is Strong. It’s a Good Sign for the Stock.\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-13 11:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.barrons.com/articles/buy-pfizer-stock-covid-19-51636674652?mod=hp_LEAD_1><strong>Barrons</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Pfizer’s chief scientific officer, Mikael Dolsten, sounded giddy when reached via telephone early Monday morning. It was just days after his company knocked the socks off the market with the news that...</p>\n\n<a href=\"https://www.barrons.com/articles/buy-pfizer-stock-covid-19-51636674652?mod=hp_LEAD_1\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞"},"source_url":"https://www.barrons.com/articles/buy-pfizer-stock-covid-19-51636674652?mod=hp_LEAD_1","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1102251183","content_text":"Pfizer’s chief scientific officer, Mikael Dolsten, sounded giddy when reached via telephone early Monday morning. It was just days after his company knocked the socks off the market with the news that its Covid-19 antiviral had cut the risk of hospitalization by 89% in high-risk adults.\n“It can’t be just a random thing, that you’re able to beat this type of world record and get a grand slam at the same time by chance,” Dolsten said, scrambling sports metaphors as he sought to illustrate the magnitude of Pfizer’s twin wins: the development of a stunningly effective Covid-19 vaccine in just 10 months, followed a year later by the development of a similarly stunning Covid-19 antiviral.\nTwo years ago, Pfizer (ticker: PFE) CEO Albert Bourla asked investors to take a big gamble on the research-and-development operation that Dolsten has rebuilt over the course of more than a decade. That bet is looking smarter than ever.\nBourla has gotten rid of Pfizer’s off-patent drugs division and the last of its consumer health products, leaving behind a pure-play biopharma company that will live or die on the strength of Dolsten’s science.\nIn a cover story in November 2019, Barron’s argued that Bourla and Dolsten could pull it off.\nThe new antiviral data reaffirms the case for Pfizer that Barron’s made two years ago. Continuing to profit off the pandemic, however, brings new risks, as criticism grows over the global inequity in vaccine distribution. Low-income nations account for less than 1% of the more than seven billion doses administered worldwide. If distribution of Pfizer’s antiviral continues to favor wealthy nations, the company’s stock could ultimately suffer.\nPfizer’s shares surged 10.9% the day the data came out, their best daily showing in at least 20 years. Still, with the stock now changing hands at around $50, investors continue to undervalue the company. Investors are pricing Pfizer at 12 times next year’s expected earnings, cheaper than peers like Johnson & Johnson (JNJ) and Eli Lilly (LLY).\nThe Pfizer discount can be attributed to concerns over the patent cliff the drugmaker faces at the end of the decade. The company stands to lose exclusivity over a handful of drugs that bring in billions in annual revenue.\nThe worries are legitimate, but Pfizer’s scientific coup should give investors confidence that the company’s science can carry it safely over that cliff. It may take time for the market to catch up, but for long-term investors, it’s a promising opportunity.\nThe success of the antiviral is the best illustration yet of Pfizer’s scientific prowess.\nWhile Pfizer’s Covid-19 vaccine came out of the labs of the German biotech BioNTech (BNTX), the new Covid-19 antiviral was whipped up by what Dolsten called a “dream team” of scientists at Pfizer’s own labs across the Northeast U.S.\nIn the earliest days of the pandemic, Pfizer split its efforts between its collaboration with BioNTech on the vaccine and its quest for a Covid-19 pill. The vaccine effort operated on a huge scale; Dolsten called it a “mega team” that spanned the Atlantic.\nThe antiviral project was a much smaller operation—a group of Pfizer experts operating with resources left over from the vaccine push.\n“The small molecule was more like a nimble, laser-focused, high-end team, with rather moderate resources,” Dolsten said.\nDolsten gathered some of Pfizer’s most experienced scientists to work on the antiviral project, including its head of medicine design, Charlotte Allerton. The scientists started with work Pfizer had done years ago on a type of antiviral called a protease inhibitor.\n“[Pfizer’s] pharmaceutical R&D is better than people had thought.”\nThe protease inhibitors in the Pfizer library, however, had been administered intravenously, and had not worked well when delivered orally. The team had to figure out how to adapt the drugs to oral administration, a substantial undertaking.\n“They had to really create a lot of new chemistry,” Dolsten said. The scientists created 600 compounds to nail down the right drug, a process that might normally take years, and which they accomplished in a matter of months. “Four years turned into four months here,” he said.\nPfizer started testing the pill in humans in March. It is now running a number of Phase 2/3 trials of the drug, including one for patients who are high risk, one for patients not high risk, and one as a prophylaxis for patients who have been exposed to the virus but aren’t yet sick. In the first readout, the drug looked substantially more effective than the Covid treatment pill from Merck (MRK).\n“It definitely helps prove the point that [Pfizer’s] pharmaceutical R&D is better than people had thought,” says Louise Chen, an analyst at Cantor Fitzgerald, who has an Overweight rating and a $61 price target on the stock.\nChen says that she doesn’t expect investors to come around to her way of thinking until there is more clarity on the durability of Covid-19 vaccine and pill sales, and the rest of the pipeline gets proved out.\n“There is not one event that I think will trigger a re-rating of the stock at the next level,” she says. “Until those things play out, I don’t think that it necessarily will.”\nThat makes a bet on Pfizer a long-term play. In the meantime, the experience of Moderna (MRNA) in recent weeks is highlighting the potential for the vaccine makers to come under scrutiny over unequal distribution of vaccines.\nBiden administration officials have been increasingly frustrated with Moderna, calling on the company to ramp up production so it can offer more doses at not-for-profit prices to low-income countries, with one top official calling on the company to “step up.”\nModerna shares are down more than 40% over the past three months.\nAs the pandemic persists, Pfizer risks eroding the enormous goodwill it earned roughly a year ago when it introduced its Covid-19 vaccine. Earlier this month, Pfizer CEO Bourla blamed low-income countries for unfair vaccine distribution, telling Barron’s that it was their fault for not placing orders. Pfizer has sold a billion vaccine doses to the U.S. at a not-for-profit price to donate to poor countries, and says that a total of at least two billion doses will be delivered to low- and middle-income nations by the end of next year.\nWhen it comes to antivirals, Pfizer has said only that it will offer tiered pricing for poorer nations, the same approach it has taken with its vaccine.\nThat contrasts sharply with Merck’s plan to make its own Covid-19 pill available to poor countries. Merck has signed a deal with a United Nations-backed group that will allow its pill to be licensed globally, with no royalties paid to Merck.\nDolsten said that Pfizer is looking into licensing its pill under a similar mechanism as Merck’s. “We will look at those options,” he said. “By no means have we said we would do something different. We just want to make sure whoever will be involved gets the advice and skill to do this.”\nSuch a step couldn’t come soon enough. Late last month, activists protested outside Bourla’s home, calling on Pfizer to share its vaccine manufacturing technology and to fill orders from low-income countries ahead of those from wealthy countries.\nAn aggressive plan to share its antiviral would help stave off such criticism, keeping Pfizer in the relative good graces of Washington and allowing its impressive science to continue to drive the stock higher.","news_type":1},"isVote":1,"tweetType":1,"viewCount":1216,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":844617599,"gmtCreate":1636422002353,"gmtModify":1636422009758,"author":{"id":"3584238171442752","authorId":"3584238171442752","name":"RyanT2021","avatar":"https://static.tigerbbs.com/c3aa70ae67b23e62ebdede4c992de8f8","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3584238171442752","idStr":"3584238171442752"},"themes":[],"htmlText":"Oh yeah AMD!","listText":"Oh yeah AMD!","text":"Oh yeah AMD!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":9,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/844617599","repostId":"2182113779","repostType":4,"isVote":1,"tweetType":1,"viewCount":867,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":845842779,"gmtCreate":1636331128796,"gmtModify":1636331128935,"author":{"id":"3584238171442752","authorId":"3584238171442752","name":"RyanT2021","avatar":"https://static.tigerbbs.com/c3aa70ae67b23e62ebdede4c992de8f8","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3584238171442752","idStr":"3584238171442752"},"themes":[],"htmlText":"Uh oh","listText":"Uh oh","text":"Uh oh","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/845842779","repostId":"1125924899","repostType":4,"repost":{"id":"1125924899","kind":"news","pubTimestamp":1636330179,"share":"https://www.laohu8.com/m/news/1125924899?lang=&edition=full","pubTime":"2021-11-08 08:09","market":"us","language":"en","title":"Supply chain problems crimp profit at Buffett's Berkshire Hathaway; cash sets record","url":"https://stock-news.laohu8.com/highlight/detail?id=1125924899","media":"Reuters","summary":"Nov 6 (Reuters) - Warren Buffett's Berkshire Hathaway Inc(BRKa.N)said on Saturday that global supply","content":"<p>Nov 6 (Reuters) - Warren Buffett's Berkshire Hathaway Inc(BRKa.N)said on Saturday that global supply chain disruptions kept a lid on its ability to generate profit, while rising equity prices caused it to sell some stocks and boost its cash hoard to a record.</p>\n<p>Operating profit rose 18% but missed analyst forecasts, as a resurgence in COVID-19 cases fueled by the Delta variant of the coronavirus caused goods shortages and crimped consumer spending, while damage from Hurricane Ida and European flooding boosted underwriting losses at the Geico car insurer and other insurance units.</p>\n<p>Net income, meanwhile, fell 66%, reflecting lower gains from stock holdings such as Apple Inc(AAPL.O)and $Bank of America Corp(BAC-N)$(BAC.N).</p>\n<p>Berkshire repurchased $7.6 billion of its own stock in the third quarter and $20.2 billion this year, as rising stock markets made buying whole companies increasingly expensive.</p>\n<p>The buybacks, which appeared to continue in October, suggest that Buffett, a 91-year-old billionaire, sees greater value in his own Omaha, Nebraska-based conglomerate, whose businesses include the BNSF railroad and namesake energy unit.</p>\n<p>\"One of the big parlor games is, what is Berkshire's next big acquisition,\" said Cathy Seifert, a CFRA Research analyst with a \"hold\" rating on Berkshire. \"I think we just saw it: it bought back $20 billion of its own stock.\"</p>\n<p>Berkshire has also been a net seller of stocks, and sold about $2 billion more stock than it bought in the quarter. It ended September with $149.2 billion of cash and equivalents.</p>\n<p>\"I sure hope there will be more buybacks, because there's not much evidence of capital being put to work,\" said Jim Shanahan, an Edward Jones &amp; Co analyst who rates Berkshire a \"buy.\"</p>\n<p>DISRUPTIONS</p>\n<p>Third-quarter operating profit rose to $6.47 billion, or about $4,331 per Class A share, from $5.48 billion, or about $3,488 per share, a year earlier.</p>\n<p>Analysts on average forecast $4,493 per share, according to Refinitiv I/B/E/S.</p>\n<p>Net income fell to $10.3 billion, or $6,882 per Class A share, from $30.1 billion. Buffett believes the huge quarterly swings in net results are usually meaningless, and result from accounting rules he doesn't control.</p>\n<p>Berkshire said supply chain disruptions have boosted prices for materials and freight, forcing businesses such as Clayton Homes mobile homes and Acme bricks to raise prices - and caused a shortage of truck drivers at McLane grocery distribution.</p>\n<p>It said the disruptions also significantly reduced new vehicle sales at its auto dealer unit and boosted costs for its consumer products businesses, though profit is rising from Forest River RVs, Brooks running shoes and Duracell batteries.</p>\n<p>In part because of Delta and the disruptions, some caused bylabor shortages, U.S. gross domestic product rose at a 2% annualized rate in the third quarter according to the government advance estimate, down from 6.7% in the second quarter.</p>\n<p>\"The supply chain creates choke points that inevitably will affect loads at Berkshire's railroad, and is creating shortages in its housing businesses,\" said Tom Russo, a partner at Gardner Russo &amp; Quinn in Lancaster, Pennsylvania, which has owned Berkshire stock since 1982.</p>\n<p>CATASTROPHE LOSSES</p>\n<p>Results reflected what analyst Shanahan called an \"extraordinarily high\" $2.2 billion of catastrophe losses, mainly from Ida and flooding, though other insurers also suffered large losses.</p>\n<p>Geico alone lost $289 million pretax from underwriting, hurt by Ida and an increase in vehicle crashes.</p>\n<p>In contrast, BNSF managed to boost profit 14% to $1.54 billion, as higher volumes in industrial goods and coal offset lower grain exports.</p>\n<p>Buffett's failure to buy more stocks and companies has disappointed some investors and analysts.</p>\n<p>It stems in part from how special purpose acquisition companies (SPACs), which take private companies public, are driving up prices of acquisition targets.</p>\n<p>\"It's a killer,\" Buffettsaidat Berkshire's annual meeting on May 1.</p>\n<p>CFRA Research analyst Seifert said Berkshire won't be sidelined forever, and might in 2022 eye acquisitions in sectors it has long favored, including industrial and consumer staples.</p>\n<p>\"Given the number of high-profile misses, such as Precision Castparts and Kraft Heinz, <a href=\"https://laohu8.com/S/AONE.U\">one</a> can understand some of Berkshire's reticence,\" she said, referring to the aircraft parts maker and food company.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Supply chain problems crimp profit at Buffett's Berkshire Hathaway; cash sets record</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSupply chain problems crimp profit at Buffett's Berkshire Hathaway; cash sets record\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-08 08:09 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.reuters.com/business/buffetts-berkshire-hathaway-boosts-operating-profit-lower-stock-gains-hurt-net-2021-11-06/><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Nov 6 (Reuters) - Warren Buffett's Berkshire Hathaway Inc(BRKa.N)said on Saturday that global supply chain disruptions kept a lid on its ability to generate profit, while rising equity prices caused ...</p>\n\n<a href=\"https://www.reuters.com/business/buffetts-berkshire-hathaway-boosts-operating-profit-lower-stock-gains-hurt-net-2021-11-06/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BRK.A":"伯克希尔","BRK.B":"伯克希尔B"},"source_url":"https://www.reuters.com/business/buffetts-berkshire-hathaway-boosts-operating-profit-lower-stock-gains-hurt-net-2021-11-06/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1125924899","content_text":"Nov 6 (Reuters) - Warren Buffett's Berkshire Hathaway Inc(BRKa.N)said on Saturday that global supply chain disruptions kept a lid on its ability to generate profit, while rising equity prices caused it to sell some stocks and boost its cash hoard to a record.\nOperating profit rose 18% but missed analyst forecasts, as a resurgence in COVID-19 cases fueled by the Delta variant of the coronavirus caused goods shortages and crimped consumer spending, while damage from Hurricane Ida and European flooding boosted underwriting losses at the Geico car insurer and other insurance units.\nNet income, meanwhile, fell 66%, reflecting lower gains from stock holdings such as Apple Inc(AAPL.O)and $Bank of America Corp(BAC-N)$(BAC.N).\nBerkshire repurchased $7.6 billion of its own stock in the third quarter and $20.2 billion this year, as rising stock markets made buying whole companies increasingly expensive.\nThe buybacks, which appeared to continue in October, suggest that Buffett, a 91-year-old billionaire, sees greater value in his own Omaha, Nebraska-based conglomerate, whose businesses include the BNSF railroad and namesake energy unit.\n\"One of the big parlor games is, what is Berkshire's next big acquisition,\" said Cathy Seifert, a CFRA Research analyst with a \"hold\" rating on Berkshire. \"I think we just saw it: it bought back $20 billion of its own stock.\"\nBerkshire has also been a net seller of stocks, and sold about $2 billion more stock than it bought in the quarter. It ended September with $149.2 billion of cash and equivalents.\n\"I sure hope there will be more buybacks, because there's not much evidence of capital being put to work,\" said Jim Shanahan, an Edward Jones & Co analyst who rates Berkshire a \"buy.\"\nDISRUPTIONS\nThird-quarter operating profit rose to $6.47 billion, or about $4,331 per Class A share, from $5.48 billion, or about $3,488 per share, a year earlier.\nAnalysts on average forecast $4,493 per share, according to Refinitiv I/B/E/S.\nNet income fell to $10.3 billion, or $6,882 per Class A share, from $30.1 billion. Buffett believes the huge quarterly swings in net results are usually meaningless, and result from accounting rules he doesn't control.\nBerkshire said supply chain disruptions have boosted prices for materials and freight, forcing businesses such as Clayton Homes mobile homes and Acme bricks to raise prices - and caused a shortage of truck drivers at McLane grocery distribution.\nIt said the disruptions also significantly reduced new vehicle sales at its auto dealer unit and boosted costs for its consumer products businesses, though profit is rising from Forest River RVs, Brooks running shoes and Duracell batteries.\nIn part because of Delta and the disruptions, some caused bylabor shortages, U.S. gross domestic product rose at a 2% annualized rate in the third quarter according to the government advance estimate, down from 6.7% in the second quarter.\n\"The supply chain creates choke points that inevitably will affect loads at Berkshire's railroad, and is creating shortages in its housing businesses,\" said Tom Russo, a partner at Gardner Russo & Quinn in Lancaster, Pennsylvania, which has owned Berkshire stock since 1982.\nCATASTROPHE LOSSES\nResults reflected what analyst Shanahan called an \"extraordinarily high\" $2.2 billion of catastrophe losses, mainly from Ida and flooding, though other insurers also suffered large losses.\nGeico alone lost $289 million pretax from underwriting, hurt by Ida and an increase in vehicle crashes.\nIn contrast, BNSF managed to boost profit 14% to $1.54 billion, as higher volumes in industrial goods and coal offset lower grain exports.\nBuffett's failure to buy more stocks and companies has disappointed some investors and analysts.\nIt stems in part from how special purpose acquisition companies (SPACs), which take private companies public, are driving up prices of acquisition targets.\n\"It's a killer,\" Buffettsaidat Berkshire's annual meeting on May 1.\nCFRA Research analyst Seifert said Berkshire won't be sidelined forever, and might in 2022 eye acquisitions in sectors it has long favored, including industrial and consumer staples.\n\"Given the number of high-profile misses, such as Precision Castparts and Kraft Heinz, one can understand some of Berkshire's reticence,\" she said, referring to the aircraft parts maker and food company.","news_type":1},"isVote":1,"tweetType":1,"viewCount":1381,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":842838016,"gmtCreate":1636160870694,"gmtModify":1636160948481,"author":{"id":"3584238171442752","authorId":"3584238171442752","name":"RyanT2021","avatar":"https://static.tigerbbs.com/c3aa70ae67b23e62ebdede4c992de8f8","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3584238171442752","idStr":"3584238171442752"},"themes":[],"htmlText":"Cheers","listText":"Cheers","text":"Cheers","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/842838016","repostId":"1173813098","repostType":4,"isVote":1,"tweetType":1,"viewCount":1203,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"defaultTab":"posts","isTTM":false}